Bristol Myers Squibb Expands Cell Therapy Portfolio with $1.5 Billion Acquisition of Orbital Therapeutics

On October 10, 2025, Bristol Myers Squibb (BMS) announced its agreement to acquire Orbital Therapeutics, a privately held biotechnology company, for $1.5 billion in cash. This acquisition aims to enhance BMS's cell therapy portfolio, particularly in the area of autoimmune diseases, by integrating Orbital's innovative RNA-based therapies and technologies.

Bristol-Myers Squibb (BMY) stock: Slides as $1.5B Orbital Therapeutics deal signals bold move into in vivo cell therapyBristol Myers Squibb Acquires Orbital Therapeutics in $1.5 Billion Deal to Expand Cell Therapy PortfolioBristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital TherapeuticsBioSpace

The centerpiece of the acquisition is Orbital's lead candidate, OTX-201, an investigational in vivo CAR T-cell therapy designed to target B-cell driven autoimmune diseases. OTX-201 utilizes engineered circular RNA delivered via lipid nanoparticles to program a patient's own T cells, potentially allowing for a more efficient and accessible treatment compared to traditional ex vivo CAR T therapies. The deal is subject to customary closing conditions, including regulatory approvals under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power PlayBMS expands CAR-T portfolio with $1.5bn Orbital buyoutBristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital TherapeuticsBenzinga

Bristol Myers Squibb is already recognized for its leadership in cell therapy, with two approved CAR T therapies: Abecma for multiple myeloma and Breyanzi for certain types of lymphoma. The acquisition of Orbital Therapeutics marks a strategic shift for BMS, expanding its focus from oncology into the broader field of autoimmune disorders, which encompass over 40 disease indications across various therapeutic areas, including rheumatology and neurology.

Bristol Myers Squibb to Acquire Orbital Therapeutics for $1.5B

Robert Plenge, BMS's Chief Research Officer, emphasized the transformative potential of in vivo CAR T therapies, stating, “This acquisition enhances our robust cell therapy research platform and provides an opportunity to advance a potential best-in-class therapy designed to deplete autoreactive B cells and reset the immune system.” Lynelle Hoch, President of BMS's Cell Therapy Organization, noted that the deal presents “an incredible opportunity to make CAR T-cell therapy more efficient and accessible to more patients.” Orbital's CEO, Ron Philip, described the agreement as a “transformational moment for Orbital and the advancement of RNA medicine.”

Bristol Myers Squibb to Acquire Orbital Therapeutics for $1.5BBristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital TherapeuticsBristol Myers Squibb to acquire Orbital for $1.5BBioSpace

Despite the optimistic outlook from BMS, analysts have expressed caution regarding the acquisition. BMO Capital Markets noted that while the potential benefits of CAR T therapies in autoimmune diseases are significant, the logistical challenges and therapeutic burden may limit their use primarily to severe patient populations. The market reaction to the announcement was muted, with BMY stock experiencing a slight decline, reflecting investor skepticism about the deal's immediate impact.

BioSpace

BMS plans to initiate clinical trials for OTX-201 in early 2026, pending the successful completion of the acquisition and regulatory approvals. The integration of Orbital's RNA platform is expected to accelerate the development of novel therapies tailored to individual patient needs, potentially transforming the treatment landscape for autoimmune diseases.

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

Bristol Myers Squibb's acquisition of Orbital Therapeutics for $1.5 billion represents a significant step in expanding its cell therapy capabilities beyond oncology into the realm of autoimmune diseases. By leveraging Orbital's innovative RNA technologies, BMS aims to enhance the efficiency and accessibility of CAR T-cell therapies, positioning itself at the forefront of next-generation treatment options in a rapidly evolving pharmaceutical landscape.

Bristol Myers Squibb Acquires Orbital Therapeutics in $1.5 Billion Deal to Expand Cell Therapy PortfolioBristol-Myers Squibb (BMY) stock: Slides as $1.5B Orbital Therapeutics deal signals bold move into in vivo cell therapyBioSpace